CLL11 is one of the of the only trials tackling the problem of CLL patients with co-morbidities, rather than younger and fitter patients, who are usually the patients enrolled in trials. Standard of care, chlorambucil was compared against rituximab plus chlorambucil and a novel CD20 antibody, obinutuzumab plus chlorambucil. Stephan Stilgenbauer, MD, PhD, from the University of Ulm, Germany, describes the results presented during the ASH2017 meeting in Atlanta, GA.
